PURPOSE: To examine predictors of weight gain following breast cancer diagnosis and subsequent return to pre-cancer weight. OBJECTIVES: To determine (1) the associations of anti-neoplastic chemotherapy and/or, Tamoxifen((R)) therapy on weight change following breast cancer diagnosis, (2) whether chemotherapy modified the effect of specific demographic and tumor characteristics on weight gain, (3) the proportion and characteristics of women who gained significant weight on chemotherapy and returned to their pre-cancer weight during follow-up. SUBJECTS AND METHODS: Participants were 3088 breast cancer survivors, aged 27-74 years. Weight was measured at baseline and years 1 through 6; pre-cancer weight was self-reported. Cancer stage and treatment modalities were obtained by medical record review; demographic and physical activity data were obtained from questionnaires. Weight gain of >/=5% body weight following cancer diagnosis was considered significant. RESULTS: Chemotherapy was significantly associated with weight gain (OR = 1.65, 95% CI = 1.12, 2.43) and Tamoxifen((R)) was not (OR = 1.03, 95% CI = 0.71, 1.51). Tamoxifen((R)) did not modify the effect of either chemotherapy or its different regimens on weight gain. Both types (anthracycline: OR = 1.63, p-value = 0.01, non-anthracycline: OR = 1.79, p = 0.003) and all regimens of chemotherapy (AC: OR = 1.55, p-value = 0.01, CAF: OR = 1.83, p = 0.003, CMF: OR = 1.76, p = 0.004) were associated with weight gain but the associations were not different from one another. Only 10% of participants returned to their pre-cancer diagnosis weight at the follow-up visits; the degree of initial gain (p for trend <0.0001) predicted that return. CONCLUSION: Chemotherapy was associated with clinically meaningful weight gain, and a return to initial weight following weight gain was unlikely.
PURPOSE: To examine predictors of weight gain following breast cancer diagnosis and subsequent return to pre-cancer weight. OBJECTIVES: To determine (1) the associations of anti-neoplastic chemotherapy and/or, Tamoxifen((R)) therapy on weight change following breast cancer diagnosis, (2) whether chemotherapy modified the effect of specific demographic and tumor characteristics on weight gain, (3) the proportion and characteristics of women who gained significant weight on chemotherapy and returned to their pre-cancer weight during follow-up. SUBJECTS AND METHODS: Participants were 3088 breast cancer survivors, aged 27-74 years. Weight was measured at baseline and years 1 through 6; pre-cancer weight was self-reported. Cancer stage and treatment modalities were obtained by medical record review; demographic and physical activity data were obtained from questionnaires. Weight gain of >/=5% body weight following cancer diagnosis was considered significant. RESULTS: Chemotherapy was significantly associated with weight gain (OR = 1.65, 95% CI = 1.12, 2.43) and Tamoxifen((R)) was not (OR = 1.03, 95% CI = 0.71, 1.51). Tamoxifen((R)) did not modify the effect of either chemotherapy or its different regimens on weight gain. Both types (anthracycline: OR = 1.63, p-value = 0.01, non-anthracycline: OR = 1.79, p = 0.003) and all regimens of chemotherapy (AC: OR = 1.55, p-value = 0.01, CAF: OR = 1.83, p = 0.003, CMF: OR = 1.76, p = 0.004) were associated with weight gain but the associations were not different from one another. Only 10% of participants returned to their pre-cancer diagnosis weight at the follow-up visits; the degree of initial gain (p for trend <0.0001) predicted that return. CONCLUSION: Chemotherapy was associated with clinically meaningful weight gain, and a return to initial weight following weight gain was unlikely.
Authors: Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen J Moore; George Davey Smith Journal: Cochrane Database Syst Rev Date: 2012-05-16
Authors: Jeanne M Ferrante; Katie A Devine; Alicja Bator; Ashley Rodgers; Pamela A Ohman-Strickland; Elisa V Bandera; Kevin O Hwang Journal: Transl Behav Med Date: 2020-10-08 Impact factor: 3.046
Authors: Christine C Ekenga; Xiaoyan Wang; Maria Pérez; Mario Schootman; Donna B Jeffe Journal: J Womens Health (Larchmt) Date: 2019-08-28 Impact factor: 2.681
Authors: M Tish Knobf; Leah M Ferrucci; Brenda Cartmel; Beth A Jones; Denise Stevens; Maureen Smith; Andrew Salner; Linda Mowad Journal: J Cancer Surviv Date: 2011-10-09 Impact factor: 4.442
Authors: Selina A Smith; Mechelle D Claridy; Mary Smith Whitehead; Joyce Q Sheats; Wonsuk Yoo; Ernest A Alema-Mensah; Benjamin E-O Ansa; Steven S Coughlin Journal: JMIR Cancer Date: 2015 Jul-Dec
Authors: Ellen B Gold; John P Pierce; Loki Natarajan; Marcia L Stefanick; Gail A Laughlin; Bette J Caan; Shirley W Flatt; Jennifer A Emond; Nazmus Saquib; Lisa Madlensky; Sheila Kealey; Linda Wasserman; Cynthia A Thomson; Cheryl L Rock; Barbara A Parker; Njeri Karanja; Vicky Jones; Richard A Hajek; Minya Pu; Joanne E Mortimer Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: Jennifer A Ligibel; Ann Partridge; Anita Giobbie-Hurder; Mehra Golshan; Karen Emmons; Eric P Winer Journal: Ann Surg Oncol Date: 2008-10-24 Impact factor: 5.344